W niniejszej publikacji zasygnalizowano jedynie wybrane wspólne cechy i powiązania dotyczące ciąży i choroby nowotworowej. Zakres szczegółowej wiedzy oraz badań dotyczących zagadnienia znacząco wykracza poza możliwości przedstawionego opracowania.

ABSTRACT

Pregnancy and cancer

Pregnancy-associated neoplasms are neoplasms diagnosed during pregnancy and within 12 months after the resolution of pregnancy. Malignancies are rarely diagnosed in pregnant women. It has not been established to date that pregnancy increases the likelihood of cancer in the mother. The most significant problems regarding pregnancy-associated cancer are early detection and appropriate treatment. The manifestations of cancer may overlap with physiological changes normally associated with pregnancy or be masked by these changes, which delays diagnosis. Pregnancy continues to be a mystery to immunologists, but the finding of a large number of similarities between pregnancy-associated processes and the development of malignancies indicates that the mechanisms of immune tolerance are similar in both settings. Future research in both areas will further enhance the management of pathological pregnancies and contribute to the development of more advanced cancer therapies.

This article only skims the issue by pointing out selected commonalities and associations between pregnancy and cancer. The amount of detailed knowledge and research on this issue is significantly beyond the limits of our article.

Piśmiennictwo

1. Rubach M, Litwiniuk M, Mądry R, et al. Cancer in pregnant women. Oncol Clin Pract 2018;14(2):62-78

2. Voulgaris E, Pentheroudakis G, Pavlidis N. Cancer and pregnancy: a comprehensive review. Surg Oncol 2011;20(4):e175-85

3. Hepner A, Negrini D, Hase EA, et al. Cancer during pregnancy: the oncologist overview. World J Oncol 2019;10(1):28-34

4. Piątek S, Bidziński M, Wielgoś M. Epidemiologia nowotworów złośliwych związanych z ciążą – stan na rok 2019. Gin Perinat Prakt 2019;4(4):145-8

5. Theriault RL, Gwyn KMEH, Hortobagyi GN. Cancer treatment during pregnancy. In: Kufe DW, Pollock RE, Weichselbaum RR, et al. (eds). Holland-Frei cancer medicine. 6th ed. Hamilton: BC Decker, 2003

6. De Haan J, Vandecaveye V, Han SN, et al. Difficulties with diagnosis of malignancies in pregnancy. Best Pract Res Clin Obstet Gynaecol 2016;33:19-32

7. Lala PK, Nandi P, Hadi A, et al. A crossroad between placental and tumor biology: what have we learnt? Placenta 2021;116:12-30

8. Holtan SG, Creedon DJ, Haluska P, et al. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc 2009;84(11):985-1000

9. Ross CA. The trophoblast model of cancer. Nutr Cancer 2015;67(1):61-7

10. Meng H, Lu CD, Sun YL, et al. Expression level of wild-type survivin in gastric cancer is an independent predictor of survival. World J Gastroenterol 2004;10(22):3245-50

11. Mahotka C, Krieg T, Krieg A, et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 2002;100(1):30-6

12. Dąbrowski A, Filip A, Zgodziński W, et al. Assessment of prognostic significance of cytoplasmic survivin expression in advanced oesophageal cancer. Folia Histochem Cytobiol 2004;42(3):179-211

13. Pande D, Negi R, Karki K, et al. Simultaneous progression of oxidative stress, angiogenesis, and cell proliferation in prostate carcinoma. Urol Oncol 2013;31(8):1561-6

14. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401-10

15. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473(7347):298-307

16. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007;130(4):691-703

17. Leite de Oliveira R, Hamm A, Mazzone M. Growing tumor vessels: more than one way to skin a cat – implications for angiogenesis targeted cancer therapies. Mol Aspects Med 2011;32(2):71-87

18. Döme B, Hendrix MJ, Paku S, et al. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 2007;170(1):1-15

19. Kilarski WW, Samolov B, Petersson L, et al. Biomechanical regulation of blood vessel growth during tissue vascularization. Nat Med 2009;15(6):657-64

20. Kurz H, Burri PH, Djonov VG. Angiogenesis and vascular remodeling by intussusception: from form to function. News Physiol Sci 2003;18:65-70

21. Stark D, Nankivell M, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 2013;14(3):236-43

22. Perren T, Swart AM, Pfisterer J, et al. ICON7: a phase III Gynaecologic Cancer InterGroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Proceedings of the European Society for Medical Oncology (ESMO) Congress. April 2011; Milan, Italy

23. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011;121(1):230-8

24. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74

Do góry